David’s reporting since 2001 has focused on the clinical aspects of medicine, particularly in the American health system. He’s covered everything from novel drugs for inflammatory bowel disease (think back to the advent of biologics!) to protocols for fine-tuning use of anticoagulants post-operatively, and from the fallout of medication compounding disasters to regulatory concerns about the 340B drug pricing program. He has covered dozens of medical conferences and profiled numerous clinicians and institutions. David is a native of Israel and lives in Toronto, Canada. His hobbies include playing music, gardening, camping and spending time with his wife, son and mini-Bernedoodle, Moishe.  

Latest from David Wild

Winning With Partnerships: How To Turn A Three-Decade-Old Biotech Profitable

Since taking on the CEO role at Theratechnologies in 2020, Paul Lévesque has made it his priority to beef up the company’s commercial portfolio and look for partnerships on potentially high-value programs. Now, the Canadian biotech is turning a profit for the first time in many years.

Google’s New Drug Discovery And Development LLM

A new large language model by Google Research and DeepMind is the most comprehensive tool yet to potentially expedite drug development and reduce the risk of failure.

Schrödinger’s Akinsanya On Low-Risk Pipeline Growth And Platform Evolution

Schrödinger has for years discovered drug candidates for other companies and derisked them, testing them in silico using its computational models. Now, it is exploring its own ability to develop drugs in the clinic, starting with low-risk bets. Will the company’s approach succeed where others have failed?

The Anatomy Of Astellas And Poseida's CAR-T Deal

Dealmakers from CAR-T biotech Poseida Therapeutics and Astellas recently sat down with In Vivo to discuss how they reached a $600m deal that combines their technologies and how they plan on moving forward.

BioBytes: AI-Related Deals in Q3 2024

The big news in Q3 2024 was the acquisition of Exscientia by Recursion, which has now expanded its pipeline and gained access to more contracts, but this quarter was also marked by numerous seed rounds and M&As, with the strengthening of existing companies and emergence of new ones into what is becoming a crowded space.  

Podcast: Alpha-Synuclein Testing Comes of Age

In the latest episode of the In Vivo podcast, Russ Lebovitz, the co-founder and scientist behind San Diego's Amprion Diagnostics, discusses the role alpha-synuclein misfolding plays in neurodegenerative diseases and how early alpha-synuclein testing could mitigate the impacts of conditions ranging from Parkinson's disease to Lewy body dementia.